Abstract 1578P
Background
Despite the beneficial findings from different clinical trials, targeted immunotherapy is still debated in advanced gastric cancer care. Immune checkpoint inhibitors (ICIs) of programmed cell death protein 1 (PD-1) have emerged as a promising therapeutic option, demonstrating clinical activity in gastric cancer. This study aims to analyze the impact of PD-1 inhibition overall survival of a large-scale series of patients treated for metastatic gastric cancer.
Methods
A retrospective study was designed by using TriNetX Platform for a large-scale search of patients with metastatic gastric cancer, who underwent immunotherapy at large healthcare organizations collaborating through TriNetX-mediated network at both European (EMEA collaborative group) and international (GLOBAL) levels. Propensity score matching was used to balance these cohorts against the cohort of metastatic gastric cancer patients not treated with PD-1 inhibitors, to remove possible confounding effect of age and gender. Kaplan Meier analysis was used to compare the 2-year overall survival of these two cohorts, after propensity score matching was used.
Results
From a total of 15.318 patients affected by metastatic gastric cancer, a cohort of 1.425 patients treated with PD-1 inhibitors was identified, including 1.372 from TriNetX healthcare organization network at a global level (TNX-GLOBAL) and 53 from the EMEA group (TNX-EMEA). When compared to the propensity score matched control patient’s cohort with no PD-1 treatment, anti-PD-1 treated patients had significantly better overall survival in both TNX-GLOBAL, 44.73% vs 41.26% (p<0.01), and in TNX-EMEA, 39.31% vs 21.47% (p<0.01).
Conclusions
The evidence from the present retrospective cohort study using real-world data from TNX-GLOBAL and TNX-EMEA collaborative networks created the unique opportunity to analyze a large-scale series of patients with metastatic gastric cancer. Positive effects of anti-PD-1-targeted therapy on survival of such a frail cohort demonstrated the clinical relevance of prevalence of PD-1 expression and supported the effectiveness of new therapies based on ICI's for metastatic disease. Given these results, further studies on the role of ICI’s also in perioperative setting are awaited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Ospedale San Raffaele.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22